TT - Theatre

The session aims to provide a practical understanding of how to recognise, assess, and manage patients with MASLD, particularly those at risk of progressive liver disease.

This promotional session is organised and funded by Recordati Pharmaceuticals Limited. Professor Derek Connolly has received a speaker honorarium from Recordati for this presentation.

Using recognisable patient scenarios, this session asks a practical question: can a patient appear well controlled based on today’s measurements while carrying a higher long-term metabolic burden? We will follow this question from the consulting room to the evidence, examining discordance between conventional risk assessment and Skin Autofluorescence (SAF). The session then turns to practice: which patients might benefit from AGE measurement, what could an unexpectedly high result trigger, and what is needed to integrate this information into existing CVRM and perioperative pathways?

This panel will explore how obesity should be understood, diagnosed and managed as part of integrated CVRM care. Panellists will discuss the difference between obesity as a risk factor, a preclinical ...

Join us for a session focussing on the use of SGLT2i for the management of cardio-renal-metabolic disease in non-diabetic patients. The panel will cover evidence, prescribing and practical insights relating to what have become foundational therapies in multiple disease states over the course of the last few years. The session will include ample time for discussion, so bring any burning questions you might have to keep things lively, interactive and informative.